Navigation Links
Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
Date:4/4/2011

HOPKINTON, Mass., April 4, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the launch of XenoLight(TM) RediJect(TM) COX-2 Probe (Fluorocoxibs), a novel fluorescent imaging agent for pre-clinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications. The COX-2 fluorescent probe technology was invented at the research laboratory of Dr. Lawrence Marnett at Vanderbilt University and is licensed to Caliper.

"COX-2 is over-expressed in a variety of inflammatory and neoplastic diseases.  The opportunity to non-invasively image COX-2 offers promise for both the early detection of disease and monitoring therapeutic response.  The fluorocoxib probe should be valuable to investigators in multiple disciplines, including cancer research," said Professor Andrew Dannenberg, Director of Cancer Center at Weill Cornell Medical College, a research leader in the field of COX-2 in oncology and inflammation.

Researchers can gain an understanding of therapeutic efficacy in specific patient populations by monitoring key biomarker response to a drug treatment.  These findings then help tailor patient-specific therapeutic strategies to improve outcomes and advance the scope of personalized medicine.  For example, COX-2 detection in tumors has become an important tool in predicting the outcome of various chemotherapy treatments, including advanced lung cancer.  Caliper's RediJect COX-2 probe provides the ability to non-invasively detect COX-2 in early-stage cancer cells, with a level of sensitivity and accuracy not attainable by conventional methods.  

"Personalized therapies to treat specific patient populations are becoming reality," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "Our partnership with Professor Lawrence Marnett, the inventor of the COX-2 probe and a prolific author and thought leader in the field, will further catalyze research in biomarker response, helping to provide insight into the development of new or rescued targeted therapies.  Caliper remains committed to providing translational research technology and services focused on further realizing the full potential of personalized medicine."

The RediJect COX-2 probe is the latest in an expanding range of reagents for Caliper's IVIS® and Maestro® optical imaging systems, and our Trio(TM), Nuance® and Vectra® tissue analysis systems. Caliper's portfolio of industry-leading pre-clinical imaging technology complements an expansive range of imaging reagents optimized to enable researchers to monitor various biological events, in live models and in excised tissue samples.  Caliper offers a variety of fluorescent and bioluminescent reagents that can be applied in a range of therapeutic areas, including oncology, infectious diseases, inflammation, neurology and stem cell research.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results that translate into potential cures for a range of diseases. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper and IVIS are registered trademarks, and XenoLight and RediJect are trademarks, of Caliper Life Sciences, Inc.  Maestro, Nuance and Vectra are registered trademarks, and Trio is a trademark, of Cambridge Research and Instruments, Inc., a wholly owned subsidiary of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
4. Caliper Awarded New Task Order for EPA ToxCast Program
5. Caliper Life Sciences Introduces Sciclone(R) G3 Liquid Handler
6. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
7. Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic
8. Caliper Life Sciences Forms Scientific Advisory Board for Next Generation Sequencing
9. Caliper Life Sciences Fourth Quarter 2009 Financial Results Conference Call Notice
10. Caliper Life Sciences and Stanford University File a Patent Infringement Lawsuit Against Carestream Health, Inc.
11. Caliper Settles Outstanding Litigation with Shimadzu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):